Andreas D Hartkopf1, Jens Huober2, Bernhard Volz3, Naiba Nabieva3, Florin-Andrei Taran1, Judith Schwitulla3, Friedrich Overkamp4, Hans-Christian Kolberg5, Peyman Hadji6, Hans Tesch7, Lothar Häberle8, Johannes Ettl9, Michael P Lux3, Diana Lüftner10, Markus Wallwiener11, Volkmar Müller12, Matthias W Beckmann3, Erik Belleville13, Pauline Wimberger14, Carsten Hielscher15, Matthias Geberth16, Nikos Fersis17, Wolfgang Abenhardt18, Christian Kurbacher19, Rachel Wuerstlein20, Christoph Thomssen21, Michael Untch22, Peter A Fasching23, Wolfgang Janni2, Tanja N Fehm24, Diethelm Wallwiener1, Sara Y Brucker1, Andreas Schneeweiss25. 1. Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany. 2. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany. 3. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany. 4. Oncologianova GmbH, Recklinghausen, Germany. 5. Marienhospital Bottrop, Bottrop, Germany. 6. Department of Bone Oncology, Nordwest Hospital, Frankfurt, Germany. 7. Oncology Practice at Bethanien Hospital Frankfurt, Germany. 8. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany; Biostatistics Unit, University Hospital Erlangen, Department of Gynecology and Obstetrics, Germany. 9. Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. 10. Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany. 11. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany. 12. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany. 13. ClinSol GmbH & Co KG, Würzburg, Germany. 14. Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany. 15. gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany. 16. Gynäkoonkologie Gemeinschaftspraxis, Praxisklinik am Rosengarten, Mannheim, Germany. 17. Department of Gynecology and Obstetrics, Klinik Hohe Warte, Bayreuth, Germany. 18. MVZ Onkologie, Onkologie im Elisenhof, München, Germany. 19. Department of Gynecology and Obstetrics, Medizinisches Zentrum Bonn Friedensplatz, Bonn, Germany. 20. Department of Gynecology and Obstetrics, Breast Center and CCC Munich, University Hospital Munich, Germany. 21. Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. 22. Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany. 23. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany. Electronic address: peter.fasching@uk-erlangen.de. 24. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Germany. 25. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
Abstract
PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed. RESULTS: This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern. CONCLUSIONS: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.
PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed. RESULTS: This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern. CONCLUSIONS: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBCpatients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.
Authors: Christoph Thomssen; Diana Lüftner; Michael Untch; Renate Haidinger; Rachel Würstlein; Nadia Harbeck; Doris Augustin; Susanne Briest; Johannes Ettl; Peter A Fasching; Frank Förster; Christian M Kurbacher; Hans-Joachim Lück; Norbert Marschner; Lothar Müller; Volkmar Müller; Lidia Perlova-Griff; Isabel Radke; Eugen Ruckhäberle; Iris Scheffen; Eva Schumacher-Wulf; Moritz Schwoerer; Dieter Steinfeld-Birg; Katja Ziegler-Löhr Journal: Breast Care (Basel) Date: 2020-02-10 Impact factor: 2.860
Authors: Peter A Fasching; Siddhartha Yadav; Chunling Hu; Marius Wunderle; Lothar Häberle; Steven N Hart; Matthias Rübner; Eric C Polley; Kun Y Lee; Rohan D Gnanaolivu; Peyman Hadji; Hanna Hübner; Hans Tesch; Johannes Ettl; Friedrich Overkamp; Michael P Lux; Arif B Ekici; Bernhard Volz; Sabrina Uhrig; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Erik Belleville; Michael Untch; Hans-Christian Kolberg; Matthias W Beckmann; André Reis; Arndt Hartmann; Wolfgang Janni; Pauline Wimberger; Florin-Andrei Taran; Tanja N Fehm; Diethelm Wallwiener; Sara Y Brucker; Andreas Schneeweiss; Andreas D Hartkopf; Fergus J Couch Journal: J Clin Oncol Date: 2021-03-29 Impact factor: 44.544
Authors: Diana Lüftner; Andreas D Hartkopf; Michael P Lux; Friedrich Overkamp; Hans Tesch; Adriana Titzmann; Patrik Pöschke; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Wolfgang Janni; Tanja N Fehm; Hans-Christian Kolberg; Johannes Ettl; Diethelm Wallwiener; Andreas Schneeweiss; Sara Y Brucker; Peter A Fasching Journal: Breast Care (Basel) Date: 2021-03-16 Impact factor: 2.860
Authors: Volkmar Müller; Achim Wöckel; Michael P Lux; Wolfgang Janni; Andreas D Hartkopf; Naiba Nabieva; Florin-Andrei Taran; Peyman Hadji; Hans Tesch; Johannes Ettl; Diana Lüftner; Manfred Welslau; Erik Belleville; Sara Y Brucker; Florian Schütz; Peter A Fasching; Tanja N Fehm; Hans-Christian Kolberg; Andreas Schneeweiss; Friedrich Overkamp Journal: Geburtshilfe Frauenheilkd Date: 2018-11-26 Impact factor: 2.915
Authors: Stephanie Stangl; Kirsten Haas; Felizitas A Eichner; Anna Grau; Udo Selig; Timo Ludwig; Tanja Fehm; Tanja Stüber; Asarnusch Rashid; Alexander Kerscher; Ralf Bargou; Silke Hermann; Volker Arndt; Martin Meyer; Manfred Wildner; Hermann Faller; Michael G Schrauder; Michael Weigel; Ulrich Schlembach; Peter U Heuschmann; Achim Wöckel Journal: Pilot Feasibility Stud Date: 2020-02-04
Authors: Thomas Decker; Ulrike Söling; Antje Hahn; Christoph Maintz; Christian Martin Kurbacher; Ursula Vehling-Kaiser; Dagmar Sent; Peter Klare; Volker Hagen; Marco Chiabudini; Julia Falkenstein; Martin Indorf; Eva Runkel; Karin Potthoff Journal: BMC Cancer Date: 2020-04-06 Impact factor: 4.430
Authors: Jennifer L Caswell-Jin; Alison Callahan; Natasha Purington; Summer S Han; Haruka Itakura; Esther M John; Douglas W Blayney; George W Sledge; Nigam H Shah; Allison W Kurian Journal: JCO Clin Cancer Inform Date: 2021-05
Authors: Manfred Welslau; Andreas D Hartkopf; Volkmar Müller; Achim Wöckel; Michael P Lux; Wolfgang Janni; Johannes Ettl; Diana Lüftner; Erik Belleville; Florian Schütz; Peter A Fasching; Hans-Christian Kolberg; Naiba Nabieva; Friedrich Overkamp; Florin-Andrei Taran; Sara Y Brucker; Markus Wallwiener; Hans Tesch; Andreas Schneeweiss; Tanja N Fehm Journal: Geburtshilfe Frauenheilkd Date: 2019-10-22 Impact factor: 2.915